These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15020030)

  • 1. Presenting and discussing nuchal translucency screening for fetal abnormality in the UK.
    Pilnick AM; Fraser DM; James DK
    Midwifery; 2004 Mar; 20(1):82-93. PubMed ID: 15020030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routinisation and constraints on informed choice in a one-stop clinic offering first trimester chromosomal antenatal screening for Down's syndrome.
    Tsouroufli M
    Midwifery; 2011 Aug; 27(4):431-6. PubMed ID: 20947230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'This is just what you do when you are pregnant': a qualitative study of prospective parents in Iceland who accept nuchal translucency screening.
    Gottfredsdóttir H; Sandall J; Björnsdóttir K
    Midwifery; 2009 Dec; 25(6):711-20. PubMed ID: 18295382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'It's something for you both to think about': choice and decision making in nuchal translucency screening for Down's syndrome.
    Pilnick A
    Sociol Health Illn; 2008 May; 30(4):511-30. PubMed ID: 18298631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the impact of screen-positive results obtained from ultrasound and biochemical screening for Down syndrome in the first trimester: a pilot study.
    Weinans MJ; Kooij L; Müller MA; Bilardo KM; Van Lith JM; Tymstra T
    Prenat Diagn; 2004 May; 24(5):347-51. PubMed ID: 15164407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-trimester pregnancy scanning as a screening tool for high-risk and abnormal pregnancies in a district general hospital setting.
    Drysdale K; Ridley D; Walker K; Higgins B; Dean T
    J Obstet Gynaecol; 2002 Mar; 22(2):159-65. PubMed ID: 12521697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midwives' perceptions of their role as facilitators of informed choice in antenatal screening.
    Ahmed S; Bryant LD; Cole P
    Midwifery; 2013 Jul; 29(7):745-50. PubMed ID: 22901497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'I want a choice, but I don't want to decide'--a qualitative study of pregnant women's experiences regarding early ultrasound risk assessment for chromosomal anomalies.
    Aune I; Möller A
    Midwifery; 2012 Feb; 28(1):14-23. PubMed ID: 21130549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuchal translucency measurement and congenital heart defects: modest association in low-risk pregnancies.
    Müller MA; Clur SA; Timmerman E; Bilardo CM
    Prenat Diagn; 2007 Feb; 27(2):164-9. PubMed ID: 17238215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nuchal translucency measurement--non invasive ultrasound screening for fetal abnormalities. Part II].
    Sieroszewski P; Baś-Budecka E
    Ginekol Pol; 2004 Mar; 75(3):192-6. PubMed ID: 15181876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative study on how Muslim women of Moroccan descent approach antenatal anomaly screening.
    Gitsels-van der Wal JT; Martin L; Manniën J; Verhoeven P; Hutton EK; Reinders HS
    Midwifery; 2015 Mar; 31(3):e43-9. PubMed ID: 25592301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making sense of the situation: women's reflection of positive fetal screening 11-21 months after giving birth.
    Kristjansdottir H; Gottfredsdottir H
    Midwifery; 2014 Jun; 30(6):643-9. PubMed ID: 24332751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Increased nuchal translucency and cystic hygroma in the first trimester: prenatal diagnosis and neonatal outcome].
    Ducarme G; Graesslin O; Alanio E; Bige V; Gaillard D; Gabriel R
    Gynecol Obstet Fertil; 2005 Oct; 33(10):750-4. PubMed ID: 16139544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midwives' views on appropriate antenatal counselling for congenital anomaly tests: do they match clients' preferences?
    Martin L; Hutton EK; Spelten ER; Gitsels-van der Wal JT; van Dulmen S
    Midwifery; 2014 Jun; 30(6):600-9. PubMed ID: 24100043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supporting choice and control? Communication and interaction between midwives and women at the antenatal booking visit.
    McCourt C
    Soc Sci Med; 2006 Mar; 62(6):1307-18. PubMed ID: 16126316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Women's expectations and experiences of childbirth.
    Gibbins J; Thomson AM
    Midwifery; 2001 Dec; 17(4):302-13. PubMed ID: 11749063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision-making on terminating pregnancy for Muslim Arab women pregnant with fetuses with congenital anomalies: maternal affect and doctor-patient communication.
    Gesser-Edelsburg A; Shahbari NA
    Reprod Health; 2017 Apr; 14(1):49. PubMed ID: 28376917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Women's opinions on the offer and use of nuchal translucency screening for Down syndrome.
    Müller MA; Bleker OP; Bonsel GJ; Bilardo CM
    Prenat Diagn; 2006 Feb; 26(2):105-11. PubMed ID: 16463289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.